FBIO Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
18.7M
+17.6%
15.9M
-12.0%
18.1M
+6.2%
17.0M
+3.7%
16.4M
Cost of Revenue
6.1M
-1.2%
6.2M
+14.3%
5.4M
-5.5%
5.8M
+16.5%
4.9M
Gross Profit
12.6M
+29.6%
9.7M
-23.3%
12.6M
+12.2%
11.3M
-1.8%
11.5M
Operating Expenses
22.6M
+28.6%
17.6M
+13.8%
15.4M
-17.4%
18.7M
-61.0%
47.9M
R&D
805.0K
+49.1%
540.0K
+247.1%
-367000
-276.4%
208.0K
-97.4%
8.1M
SG&A
20.8M
+30.9%
15.9M
+7.9%
14.7M
-15.4%
17.4M
-55.1%
38.8M
Operating Income
-10006000
-27.4%
-7856000
-182.7%
-2779000
+62.5%
-7417000
+79.7%
-36473000
EBITDA
-8943000
-34.7%
-6637000
-309.2%
-1622000
+74.1%
-6260000
+82.3%
-35317000
Net Income
602.0K
-99.6%
137.2M
+2641.4%
-5397000
-161.1%
8.8M
+175.7%
-11654000
EPS (Basic)
$-0.08
-102.3%
$3.44
+1820.0%
$-0.20
-253.8%
$0.13
-74.0%
$0.50
EPS (Diluted)
$-0.08
-102.8%
$2.82
+1107.1%
$-0.28
-354.5%
$0.11
-75.6%
$0.45
Shares (Diluted)
31.8M
-17.2%
38.4M
+72.8%
22.2M
-32.8%
33.1M
+11.0%
29.8M
Fortress Biotech (FBIO) โ€” Financials